Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CNS companies join forces

June 19, 2006 | A version of this story appeared in Volume 84, Issue 25

Axonyx and TorreyPines Therapeutics will merge to create a biopharmaceutical company focused on drugs for central nervous system disorders. The new company will keep the TorreyPines Therapeutics name and have its headquarters in San Diego. The combined pipeline boasts eight products in development: two to treat chronic pain and six to treat Alzheimer's disease. The companies plan to seek a partner for the most advanced candidate, Axonyx's Phenserine, now in Phase III trials for Alzheimer's disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.